| Name | Title | Contact Details |
|---|---|---|
Brianna Gerber |
Chief Financial Officer | Profile |
Jenny Robles |
Director, People Matter(s) | Profile |
Aron Erickson |
Vice President of R&D | Profile |
Yasmeen Nkrumah-Elie |
Global Director of R&D for External Research | Profile |
Philip Redpath |
Director, R&D | Profile |
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Solera is changing lives by guiding people to better health solutions that work. Solera`s value-based technology platform enables successful interventions that address the most prevalent and costly chronic conditions. Solera matches consumers to their best-fit solution within carefully curated networks of digital and community-based point solutions and drives superior engagement and outcomes by managing performance. Solera`s technology platform serves payers and employers by streamlining, integrating, and creating accountability in the point solution ecosystem.
NeoLife is a pioneer in whole food nutrition supplementation since 1958, with a commitment to end the trend of poor wellness and poverty.
The NCH Healthcare System is a not-for-profit multi-facility healthcare system located in Naples, Florida. The system includes two hospitals (NCH Healthcare System – Downtown Naples Hospital and NCH Healthcare System – North Naples Hospital) with a total of 681 beds collaborating with 630 physicians to care for more than 32,000 patients each year. Outpatient facilities include Walk-in Centers, Wellness Centers, Rehabilitation Centers, Wound Care Facilities, and Infusion Centers in Naples, North Naples, Marco Island, Bonita Springs, and Estero. NCH`s Emergency Departments and outpatient facilities had over 120,000 visits for the past two years. Caring for all ages in the communities it serves, NCH performs almost 500 open heart surgeries and 3,400 newborn deliveries each year.
Complexity in our healthcare system is standing in the way of people accessing care they need. It`s also driving crippling costs. We utilize our deep expertise in influencing consumer behavior to drive better healthcare decisions, increase quality and decrease costs.